MedTrace Logo

Tucidinostat and Nab-paclitaxel in Advanced HR+/HER2- Breast Cancer

NCT05633914 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2023-02-21

No results posted yet for this study

Summary

This study is looking to see whether the combination of Tucidinostat and nab-paclitaxel is safe and effective in participants with advanced HR+/HER2- breast cancer.

Conditions

  • HR+/HER2- Breast Cancer

Interventions

DRUG

Tucidinostat

20mg, po., biw, q3w

DRUG

nab-paclitaxel

125mg/m2, d1, iv.drip, q7d

Sponsors & Collaborators

  • Hunan Cancer Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-07
Primary Completion
2024-12-01
Completion
2025-12-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05633914 on ClinicalTrials.gov